Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-06-23FDA Approved: MEKINIST — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for MEKINIST (trametinib) filed by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2020-06-18Clinical Trial Update: Immunotherapy of Stage III/IV Melanoma Patients [Phase 1]
Phase 1 immunotherapy trial in stage III/IV melanoma completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma [Phase 3]
Phase 3 trial comparing cobimetinib plus atezolizumab versus pembrolizumab in previously untreated advanced BRAFV600 wild-type melanoma; stu…
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma [Phase 1, Phase 2]
A clinical trial investigating an IDO inhibitor in combination with checkpoint inhibitors for metastatic melanoma has completed Phase 1/2 st…
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy [Phase 2]
Phase 2 trial evaluating induction therapy with vemurafenib and cobimetinib to optimize subsequent nivolumab and ipilimumab therapy in melan…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-05-28Clinical Trial Update: Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma [Phase 2]
Phase 2 trial updating efficacy and safety of talimogene laherparepvec plus neoadjuvant surgery versus surgery alone for completely resectab…
-
CLINICAL_TRIALS trial_result · 2020-05-26Clinical Trial Update: Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation [Phase 2]
Phase 2 trial evaluating adjuvant dabrafenib (BRAFV600E/K) in surgically resected AJCC Stage IIIC melanoma with BRAFV600E/K mutation has com…
-
CLINICAL_TRIALS trial_result · 2020-05-21Clinical Trial Update: Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma [Phase 2]
Phase 2 trial update evaluating camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma.
-
CLINICAL_TRIALS trial_result · 2020-05-20Clinical Trial Update: Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma [Phase 1, Phase 2]
Phase 1/2 trial of CDX-3379 with trametinib in advanced NRAS-mutant or WT melanoma was terminated; no results posted in the snippet.
-
CLINICAL_TRIALS trial_result · 2020-05-19Clinical Trial Update: A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine [Phase 3]
Phase 3 trial comparing ipilimumab (3 mg/kg) to dacarbazine in chemotherapy-naïve stage IV melanoma in Chinese subjects; results posted.
-
FDA approval · 2020-05-18FDA Approved: ZELBORAF — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Zelboraf (vemurafenib) submitted by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2020-04-29Clinical Trial Update: Immunotherapy Study for Patients With Stage IV Melanoma [Phase 2]
Phase 2 clinical trial update for an immunotherapy study in stage IV/metastatic melanoma; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer [Phase 1, Phase 2]
Phase 1/2 trial of an individualized mRNA cancer vaccine targeting neoantigens in autologous tumors; study terminated with results posted in…
-
CLINICAL_TRIALS trial_result · 2020-04-09Clinical Trial Update: Flavopiridol in Treating Patients With Metastatic Malignant Melanoma [Phase 2]
Phase 2 trial investigating flavopiridol for metastatic malignant melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2020-04-09Clinical Trial Update: A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma [NA]
The clinical trial evaluating PLX3397 (pexidartinib) in patients with unresectable or metastatic KIT-mutated melanoma has completed, with re…
-
FDA approval · 2020-04-08FDA Approved: BRAFTOVI — Supplemental Application (Array BioPharma Inc.)
The FDA approved a supplemental application for BRAFTOVI (encorafenib) filed by Array BioPharma Inc., resulting in an updated indication/lab…
-
CLINICAL_TRIALS trial_result · 2020-03-20Clinical Trial Update: Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients [Phase 1, Phase 2]
Phase 1/2 trial update on immunotherapy for HLA-A2 positive stage II-IV melanoma; trial terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-11Clinical Trial Update: Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma [Phase 2]
This Phase 2 study evaluated the combination of ipilimumab and nivolumab in patients with melanoma. The trial has completed and results were…
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Ipilimumab + Temozolomide in Metastatic Melanoma [Phase 2]
A Phase 2 trial evaluating the combination of ipilimumab and temozolomide in metastatic melanoma has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-27Clinical Trial Update: A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients [Phase 2]
Phase 2 clinical trial update evaluating safety and efficacy of OrienX010 in unresectable malignant melanoma.
-
CLINICAL_TRIALS trial_result · 2020-02-24Clinical Trial Update: Vemurafenib and TIL Therapy for Metastatic Melanoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating vemurafenib in combination with tumor-infiltrating lymphocyte (TIL) therapy for metastatic melano…
-
CLINICAL_TRIALS trial_result · 2020-02-24Clinical Trial Update: Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery [Phase 2]
Phase 2 clinical trial evaluating dasatinib for locally advanced or metastatic mucosal, acral, or vulvovaginal melanomas that are unresectab…
-
CLINICAL_TRIALS trial_result · 2020-02-20Clinical Trial Update: A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) [Phase 2]
Phase 2 single-arm trial of nivolumab in unresectable stage III/IV melanoma after anti-CTLA-4 treatment; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-20Clinical Trial Update: Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer [Phase 4]
A Phase 4 clinical trial comparing Lymphoseek to Albumin Nanocolloid in head and neck cancers, melanoma, and breast cancer is ongoing with u…
-
CLINICAL_TRIALS trial_result · 2020-02-19Clinical Trial Update: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI [Phase 2]
Phase 2 trial of high-dose interleukin-2 combined with recMAGE-A3 + AS15 for melanoma has completed with posted results.